FindTrial
Sign In

Modification of Jivantyadi Yamaka into Malahara and its Clinical Efficacy in Psoriasis

Pharmaceutical Development of Jivantyadi Yamaka into Malahara and their Comparative Clinical Efficacy in Ekakustha (Psoriasis)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/04/032979
Enrollment
30
Registered
2021-04-20
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L00-L99- Diseases of the skin and subcutaneous tissue

Interventions

Intervention1: Jivantyadi Yamaka and placebo: Jivantyadi Yamaka OD - at night [Quantity sufficient for local application of affected part of the body] Placebo 2 capsules BD- after meal Control Int

Sponsors

Government Ayurved Hospital Vadodara
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with all forms of Ekakushtha (Psoriasis) with classical signs & symptoms of Ekakushtha (Psoriasis) All type of psoriasis will be included Less than 20 % involved area according to PASI guidelines

Exclusion criteria

Exclusion criteria: More than 20 % involved area according to PASI guidelines Age 60yrs. Pregnant women and lactating mother Uncontrolled Diabetes Mellitus & Hypertension Any other serious systemic illness like AIDS, Malignancy etc �Patients who are not willing to be included in the study

Design outcomes

Primary

MeasureTime frame
Change in the Classical Symptoms of Ekakushtha (Psoriasis)Timepoint: 35 days—

Secondary

MeasureTime frame
Difference in Clinical efficacy of Jivantyadi Yamaka and Malahara in Ekakushtha (Psoriasis)Timepoint: 35 days—

Countries

India

Contacts

Public ContactDr Kruti Vyas

Government Ayurved College, Vadodara

dr.bhartiumrethia@gmail.com7600011944

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026